Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown a recent net value increase of 2.02% and a year-to-date return of 39.18% [1] - The fund's recent performance includes a one-month return of -0.39%, a six-month return of 25.97%, and a year-to-date return ranking of 40 out of 4544 in its category [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed A fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A fund since July 1, 2022, and has also taken on management roles for other funds within the Zhongyin family [2]
5月27日中银创新医疗混合A净值增长2.02%,今年来累计上涨39.18%